According to the IMS Institute, biologics account for 27% of the pharmaceutical sales in the EU and grew at at 5.5% vs. a total market growth of 1.9% between 2012 and 2013.

They constitute eight of the EU’s top ten selling products and all of these leading biologics are either already off patent or facing patent expiration by 2020, creating a major opportunity for biosimilars.

The following article by one of Cognite’s Global collaborators, an independent research driven strategy consultant, Donna Vetter, sums up the situation well and hopefully will give you some food for thought.

Download the Donna Vetter article here.